Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion type Assertion NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_head.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion wasGeneratedBy ECO_0000203 NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion wasDerivedFrom befree-2016 NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion SIO_000772 23932550 NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion evidence source_evidence_literature NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion description "[Although the use of mipomersen and lomitapide is limited to severe familial hypercholesterolemia as a replacement for LDL-apheresis, PCSK9 inhibitors are likely to be more widely prescribed in patients at high risk for CVD, especially those who are resistant to or intolerant of high-intensity statin therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.